LU91364I2 - Alendronate de sodium /colécalciférol - Google Patents

Alendronate de sodium /colécalciférol

Info

Publication number: LU91364I2
Authority: LU; Luxembourg
Prior art keywords: disclosed; colecalciferol; sodium alendronate; alendronate; methods
Prior art date: 1997-07-22

Application number

LU91364C

Other languages

English (en)

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-22

Filing date

2007-09-12

Publication date

2007-11-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91364(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-08-20 Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en

1997-08-22 Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en

2007-09-12 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

2007-11-12 Publication of LU91364I2 publication Critical patent/LU91364I2/fr

Links

QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 title 1
DCSBSVSZJRSITC-UHFFFAOYSA-M alendronate sodium trihydrate Chemical compound O.O.O.[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O DCSBSVSZJRSITC-UHFFFAOYSA-M 0.000 title 1
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 title 1
235000005282 vitamin D3 Nutrition 0.000 title 1
239000011647 vitamin D3 Substances 0.000 title 1
229940021056 vitamin d3 Drugs 0.000 title 1
-1 etridronate Chemical compound 0.000 abstract 2
OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 abstract 1
229940122361 Bisphosphonate Drugs 0.000 abstract 1
208000006386 Bone Resorption Diseases 0.000 abstract 1
MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 abstract 1
DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 abstract 1
230000002411 adverse Effects 0.000 abstract 1
229940062527 alendronate Drugs 0.000 abstract 1
150000004663 bisphosphonates Chemical class 0.000 abstract 1
230000024279 bone resorption Effects 0.000 abstract 1
ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 abstract 1
229960002286 clodronic acid Drugs 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000002496 gastric effect Effects 0.000 abstract 1
239000003485 histamine H2 receptor antagonist Substances 0.000 abstract 1
229940015872 ibandronate Drugs 0.000 abstract 1
LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 abstract 1
229950006971 incadronic acid Drugs 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 abstract 1
229940046231 pamidronate Drugs 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229940089617 risedronate Drugs 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
229940019375 tiludronate Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Compounds Of Unknown Constitution (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Hydrogenated Pyridines (AREA)
Saccharide Compounds (AREA)
Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)

LU91364C 1997-07-22 2007-09-12 Alendronate de sodium /colécalciférol LU91364I2 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US5335197P	1997-07-22	1997-07-22
US5353597P	1997-07-23	1997-07-23
GBGB9717590.5A GB9717590D0 (en)	1997-08-20	1997-08-20	Oral method for treating or preventing abnormal bone resorption
GBGB9717850.3A GB9717850D0 (en)	1997-08-22	1997-08-22	Oral method for treating or preventing abnormal bone resorption
EP98935752A EP0998292B1 (fr)	1997-07-22	1998-07-17	Procede d'inhibition de resorption osseuse

Publications (1)

Publication Number	Publication Date
LU91364I2 true LU91364I2 (fr)	2007-11-12

Family

ID=27451690

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LU91222C LU91222I2 (fr)	1997-07-22	2006-02-15	Alendronate sodium(colecalciferol et ses dérivés pharmaceutiquement acceptables (fosavance)
LU91364C LU91364I2 (fr)	1997-07-22	2007-09-12	Alendronate de sodium /colécalciférol

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
LU91222C LU91222I2 (fr)	1997-07-22	2006-02-15	Alendronate sodium(colecalciferol et ses dérivés pharmaceutiquement acceptables (fosavance)

Country Status (31)

Country	Link
EP (5)	EP1175904B8 (fr)
JP (2)	JP3479780B2 (fr)
KR (3)	KR20030097611A (fr)
CN (3)	CN1602879A (fr)
AT (2)	ATE357921T1 (fr)
AU (1)	AU8493698A (fr)
BG (1)	BG66282B1 (fr)
BR (1)	BR9810779A (fr)
CA (1)	CA2294595C (fr)
CY (2)	CY1107535T1 (fr)
DE (6)	DE69803291T2 (fr)
DK (2)	DK0998292T3 (fr)
EA (1)	EA004544B2 (fr)
EE (1)	EE05603B1 (fr)
ES (3)	ES2253136T1 (fr)
HK (4)	HK1042230A1 (fr)
ID (1)	ID24096A (fr)
IL (1)	IL133535A0 (fr)
IS (3)	IS5315A (fr)
LU (2)	LU91222I2 (fr)
NL (2)	NL300223I1 (fr)
NO (1)	NO20000323L (fr)
NZ (1)	NZ501807A (fr)
PL (1)	PL195272B1 (fr)
PT (2)	PT998292E (fr)
SG (2)	SG139556A1 (fr)
SI (1)	SI0998292T1 (fr)
SK (1)	SK932000A3 (fr)
TR (1)	TR200000145T2 (fr)
UY (1)	UY25950A1 (fr)
WO (1)	WO1999004773A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3219402B2 (ja)	1998-12-25	2001-10-15	山之内製薬株式会社	多発性骨髄腫の骨病変治療用医薬組成物
EP1178810B8 (fr) *	1999-05-21	2005-07-27	Novartis AG	Utilisation d'acide biphosphonique pour traiter l'angiogenese
EP1114642B1 (fr) *	1999-07-19	2010-01-06	Toray Industries, Inc.	Medicaments pour soigner les parodontopathies
WO2001046040A1 (fr)	1999-12-20	2001-06-28	Merck & Co., Inc.	Plaquette alveolaire pour carte de traitement pharmaceutique
WO2001045636A1 (fr) *	1999-12-20	2001-06-28	Merck & Co., Inc.	Trousse pharmaceutique
WO2001076577A2 (fr) *	2000-04-07	2001-10-18	The Board Of Regents Of The University Of Texas System	Compositions uniques de phospholipides zwitterioniques et de bisphosphonates et leur utilisation sous forme de systemes d'administration de bisphosphates presentant une toxicite gastro-intestinale limitee
DK1296689T3 (da)	2000-06-20	2005-11-28	Novartis Ag	Fremgangsmåde til indgivelse af bisphosphonater
EP1591122B1 (fr) *	2000-06-20	2012-09-26	Novartis AG	Méthode pour l'administration de biphosphonates
US6638920B2 (en) *	2000-07-21	2003-10-28	Merck & Co., Inc.	Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv) *	2001-04-18	2001-04-18	Diabact Ab	Komposition som hämmar utsöndring av magsyra
BR0209360A (pt) *	2001-05-02	2004-06-08	Novartis Ag	Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose
BR0308901A (pt) *	2002-05-10	2005-01-04	Hoffmann La Roche	ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
SE0203065D0 (sv)	2002-10-16	2002-10-16	Diabact Ab	Gastric acid secretion inhibiting composition
AU2004273672A1 (en) *	2003-09-19	2005-03-31	Wisconsin Alumni Research Foundation	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate
WO2005072747A1 (fr) *	2004-02-02	2005-08-11	Ono Pharmaceutical Co., Ltd.	Inhibiteurs de resorption osseuse
NZ567200A (en) *	2005-09-16	2010-08-27	Selamine Ltd	Bisphosphonate formulation
US9592195B2 (en) *	2010-12-06	2017-03-14	Effrx Pharmaceuticals Sa	Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
CN106924257B (zh) *	2017-03-14	2019-11-19	湖南赛隆药业有限公司	质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL84731A0 (en) *	1986-12-19	1988-05-31	Norwich Eaton Pharma	Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) *	1987-11-13	1987-11-13	Pm Konsult Handelsbolag	Anvendning av antisekretoriska substanser for nya indikationer
ATE122228T1 (de) *	1991-07-01	1995-05-15	Gergely Gerhard	Verfahren zur herstellung einer pharmazeutischen zubereitung mit wenigstens zwei verschiedenen wirkstoffen und verwendung einer solchen zubereitung.
CZ282760B6 (cs) *	1991-11-22	1997-09-17	Procter And Gamble Pharmaceuticals, Inc.	Risedronátové prostředky se zpožděným uvolňováním
US5270365A (en) *	1991-12-17	1993-12-14	Merck & Co., Inc.	Prevention and treatment of periodontal disease with alendronate
US5294433A (en) *	1992-04-15	1994-03-15	The Procter & Gamble Company	Use of H-2 antagonists for treatment of gingivitis
ES2111163T3 (es) *	1992-06-30	1998-03-01	Procter & Gamble Pharma	Uso de fosfonatos para el tratamiento de la osteoporosis.
US5431920A (en) *	1993-09-21	1995-07-11	Merck Frosst, Canada, Inc.	Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) *	1994-04-21	1997-07-08	Merck & Co., Inc.	Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
EP0831843A1 (fr) *	1995-06-06	1998-04-01	Merck & Co., Inc.	Traitement par bisphosphonates de la deperdition osseuse associee a l'arthrite rhumatoide
DE69726879T2 (de) *	1996-05-17	2004-10-14	Merck & Co., Inc.	Biphosphonat-formulierung mit brausewirkung

1998
- 1998-07-17 DE DE69803291T patent/DE69803291T2/de not_active Revoked
- 1998-07-17 EP EP01201913A patent/EP1175904B8/fr not_active Revoked
- 1998-07-17 KR KR1020027013595A patent/KR20030097611A/ko not_active Ceased
- 1998-07-17 WO PCT/US1998/014796 patent/WO1999004773A2/fr not_active Ceased
- 1998-07-17 SK SK93-2000A patent/SK932000A3/sk not_active Application Discontinuation
- 1998-07-17 DE DE01201913T patent/DE01201913T1/de active Pending
- 1998-07-17 EA EA200000151A patent/EA004544B2/ru not_active IP Right Cessation
- 1998-07-17 ES ES01201910T patent/ES2253136T1/es active Pending
- 1998-07-17 EP EP98935752A patent/EP0998292B1/fr not_active Revoked
- 1998-07-17 EE EEP200000040A patent/EE05603B1/xx unknown
- 1998-07-17 DE DE01201911T patent/DE01201911T1/de active Pending
- 1998-07-17 ID IDW20000114A patent/ID24096A/id unknown
- 1998-07-17 CN CNA2004100557346A patent/CN1602879A/zh active Pending
- 1998-07-17 PT PT98935752T patent/PT998292E/pt unknown
- 1998-07-17 PT PT01201913T patent/PT1175904E/pt unknown
- 1998-07-17 CN CNB2004100557350A patent/CN1299689C/zh not_active Expired - Lifetime
- 1998-07-17 EP EP01201912A patent/EP1175903A3/fr not_active Ceased
- 1998-07-17 SG SG200603406-0A patent/SG139556A1/en unknown
- 1998-07-17 KR KR1020027013594A patent/KR20030097610A/ko not_active Ceased
- 1998-07-17 AT AT01201913T patent/ATE357921T1/de active
- 1998-07-17 CN CNB988074737A patent/CN1166365C/zh not_active Ceased
- 1998-07-17 BR BR9810779-8A patent/BR9810779A/pt not_active Application Discontinuation
- 1998-07-17 JP JP50991499A patent/JP3479780B2/ja not_active Expired - Lifetime
- 1998-07-17 CA CA002294595A patent/CA2294595C/fr not_active Expired - Fee Related
- 1998-07-17 DE DE69837450T patent/DE69837450T2/de not_active Expired - Lifetime
- 1998-07-17 IL IL13353598A patent/IL133535A0/xx unknown
- 1998-07-17 SI SI9830086T patent/SI0998292T1/xx unknown
- 1998-07-17 DE DE1998603291 patent/DE122006000009I1/de active Pending
- 1998-07-17 TR TR2000/00145T patent/TR200000145T2/xx unknown
- 1998-07-17 ES ES01201913T patent/ES2269014T3/es not_active Expired - Lifetime
- 1998-07-17 EP EP01201911A patent/EP1151752A3/fr not_active Ceased
- 1998-07-17 DE DE200712000063 patent/DE122007000063I1/de active Pending
- 1998-07-17 PL PL98338635A patent/PL195272B1/pl unknown
- 1998-07-17 DK DK98935752T patent/DK0998292T3/da active
- 1998-07-17 NZ NZ501807A patent/NZ501807A/en not_active IP Right Cessation
- 1998-07-17 DK DK01201913T patent/DK1175904T3/da active
- 1998-07-17 ES ES98935752T patent/ES2164447T3/es not_active Expired - Lifetime
- 1998-07-17 AU AU84936/98A patent/AU8493698A/en not_active Abandoned
- 1998-07-17 KR KR1020007000680A patent/KR100391732B1/ko not_active Expired - Fee Related
- 1998-07-17 AT AT98935752T patent/ATE209037T1/de active
- 1998-07-17 SG SG200107221A patent/SG109478A1/en unknown
- 1998-07-17 EP EP01201910A patent/EP1132088A3/fr not_active Ceased
1999
- 1999-12-21 IS IS5315A patent/IS5315A/is unknown
2000
- 2000-01-17 UY UY25950A patent/UY25950A1/es not_active Application Discontinuation
- 2000-01-18 BG BG104093A patent/BG66282B1/bg unknown
- 2000-01-21 NO NO20000323A patent/NO20000323L/no unknown
2002
- 2002-03-04 HK HK02101656.1A patent/HK1042230A1/en unknown
- 2002-03-12 HK HK02101869.4A patent/HK1042232A1/en unknown
- 2002-03-16 HK HK02102042.2A patent/HK1040494A1/en unknown
- 2002-03-16 HK HK02102043.1A patent/HK1040495A1/en unknown
2003
- 2003-03-10 JP JP2003063378A patent/JP2005068010A/ja active Pending
2004
- 2004-04-21 IS IS7231A patent/IS7231A/is unknown
- 2004-04-21 IS IS7230A patent/IS7230A/is unknown
2006
- 2006-02-07 NL NL300223C patent/NL300223I1/nl unknown
- 2006-02-15 LU LU91222C patent/LU91222I2/fr unknown
2007
- 2007-03-29 CY CY20071100442T patent/CY1107535T1/el unknown
- 2007-09-12 LU LU91364C patent/LU91364I2/fr unknown
- 2007-09-13 NL NL300292C patent/NL300292I1/nl unknown
- 2007-09-20 CY CY2007022C patent/CY2007022I1/el unknown

Also Published As

Publication number	Publication date
EP0998292B1 (fr)	2001-11-21
JP2002502433A (ja)	2002-01-22
CN1299689C (zh)	2007-02-14
IS5315A (is)	1999-12-21
TR200000145T2 (tr)	2000-05-22
EP1175904A2 (fr)	2002-01-30
ATE357921T1 (de)	2007-04-15
JP2005068010A (ja)	2005-03-17
CN1265035A (zh)	2000-08-30
EP1175904B8 (fr)	2007-05-09
ID24096A (id)	2000-07-06
PT1175904E (pt)	2007-04-30
EP1175903A3 (fr)	2002-12-18
DK1175904T3 (da)	2007-05-07
PL338635A1 (en)	2000-11-06
EE200000040A (et)	2000-10-16
EP1151752A2 (fr)	2001-11-07
EP0998292A2 (fr)	2000-05-10
NZ501807A (en)	2003-02-28
SK932000A3 (en)	2000-09-12
HK1040494A1 (en)	2002-06-14
EA004544B1 (ru)	2004-06-24
CN1602880A (zh)	2005-04-06
EP1132088A3 (fr)	2002-04-24
KR100391732B1 (ko)	2003-07-16
ATE209037T1 (de)	2001-12-15
DE69837450D1 (de)	2007-05-10
SG109478A1 (en)	2005-03-30
KR20030097611A (ko)	2003-12-31
EA200000151A1 (ru)	2000-10-30
BG66282B1 (bg)	2013-01-31
DE122006000009I1 (de)	2006-06-14
EP1175904B1 (fr)	2007-03-28
CN1166365C (zh)	2004-09-15
CY2007022I2 (el)	2012-01-25
ES2269014T1 (es)	2007-04-01
DE122007000063I1 (de)	2007-12-20
ES2269014T3 (es)	2007-05-01
AU8493698A (en)	1999-02-16
NO20000323L (no)	2000-03-20
EP1132088A2 (fr)	2001-09-12
DE01201913T1 (de)	2007-02-08
PT998292E (pt)	2002-04-29
IS7230A (is)	2004-04-21
KR20010022110A (ko)	2001-03-15
CA2294595C (fr)	2001-08-21
EP1175904A3 (fr)	2002-12-18
LU91222I2 (fr)	2006-04-18
ES2253136T1 (es)	2006-06-01
IS7231A (is)	2004-04-21
EA004544B2 (ru)	2006-12-29
NL300292I1 (nl)	2007-11-01
DE69803291D1 (de)	2002-02-21
ES2164447T3 (es)	2002-02-16
HK1024166A1 (en)	2000-10-05
CY2007022I1 (el)	2012-01-25
WO1999004773A2 (fr)	1999-02-04
CY1107535T1 (el)	2012-01-25
NO20000323D0 (no)	2000-01-21
SG139556A1 (en)	2008-02-29
HK1042232A1 (en)	2002-08-09
NL300223I1 (nl)	2006-04-03
PL195272B1 (pl)	2007-08-31
JP3479780B2 (ja)	2003-12-15
SI0998292T1 (en)	2002-04-30
DE69837450T2 (de)	2007-08-23
UY25950A1 (es)	2000-09-29
EP1175903A2 (fr)	2002-01-30
BG104093A (en)	2000-10-31
WO1999004773A9 (fr)	1999-10-28
WO1999004773A3 (fr)	1999-04-15
DE69803291T2 (de)	2002-08-08
HK1040495A1 (en)	2002-06-14
KR20030097610A (ko)	2003-12-31
HK1042230A1 (en)	2002-08-09
EP1151752A3 (fr)	2002-12-18
IL133535A0 (en)	2001-04-30
CN1602879A (zh)	2005-04-06
DE01201911T1 (de)	2007-10-18
BR9810779A (pt)	2000-07-25
DK0998292T3 (da)	2002-05-13
EE05603B1 (et)	2012-12-17
CA2294595A1 (fr)	1999-02-04

Publication	Publication Date	Title
NL300292I1 (nl)	2007-11-01	Werkwijze voor het inhibiteren van botresorptie
NZ272608A (en)	2000-05-26	Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts
NZ545804A (en)	2009-09-25	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate
HRP20020594B1 (en)	2011-03-31	Pharmaceutical parenteral composition containing a biphosphonate
DK1296689T3 (da)	2005-11-28	Fremgangsmåde til indgivelse af bisphosphonater
BR0309691A (pt)	2005-08-02	Formulação de ibandronato em alta dose
YU1800A (sh)	2002-08-12	Upotreba bisfosfonata za proizvodnju leka za inhibiranje resorpcije kostiju
BR9609477A (pt)	1999-05-25	Composto composição farmacêutica e processos para preparação de tiludronato dissódico e para obtenção de uma composição farmacêutica
TWI226833B (en)	2005-01-21	Pharmaceutical composition for inhibiting bone resorption